Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2021 Jul 1;131(13):e152477. doi: 10.1172/JCI152477

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

Meenakshi Hegde, Malini Mukherjee, Zakaria Grada, Antonella Pignata, Daniel Landi, Shoba A Navai, Amanda Wakefield, Kristen Fousek, Kevin Bielamowicz, Kevin KH Chow, Vita S Brawley, Tiara T Byrd, Simone Krebs, Stephen Gottschalk, Winfried S Wels, Matthew L Baker, Gianpietro Dotti, Maksim Mamonkin, Malcolm K Brenner, Jordan S Orange, Nabil Ahmed
PMCID: PMC8245163  PMID: 34196303

Original citation: J Clin Invest. 2016;126(8):3036–3052. https://doi.org/10.1172/JCI83416

Citation for this amendment: J Clin Invest. 2021;131(13):e152477. https://doi.org/10.1172/JCI152477

The Editors posted an Expression of Concern for this article following notification that two images in Figure 9D were subsequently published as distinct samples in another paper (1). An institutional review of the primary data supports that the images in the JCI article are correct and that no corrective action is required.

Version 1. 07/01/2021

Electronic publication

Footnotes

References

  • 1.Bielamowicz K, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018;20(4):506–518. doi: 10.1093/neuonc/nox182. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES